+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for children with hepatoblastoma, a common liver cancer in babies and very young children, and rhabdomyosarcoma RMS, a cancer that starts in muscle cells often found in the head and neck, bladder, arms, or legs. This study focuses on cases where these cancers have returned after treatment or did not respond to previous therapies. The research aims to understand the safety and behavior of a study drug called HER3-DXd patritumab deruxtecan in children and its effects on shrinking or eliminating cancer. Participants receive patritumab deruxtecan through an intravenous infusion on the first day of each 3-week cycle and continue until the cancer progresses or they stop the treatment. The study has two parts the first evaluates safety and determines the best dose, while the second assesses how well the drug works. This approach helps to find a safe and effective dose for children with these cancers. During the study, children will be closely monitored for side effects and treatment responses. Blood samples will be collected to study how the drug is processed in the body over time. Researchers will measure outcomes such as tumor response, time to response, and disease control for up to approximately five years. Participants will also be followed long-term to assess overall safety and effectiveness throughout the study period.

Age: 1Month - 17YearsAll GendersPhase 1Phase 2
64 locations
C

Actively Recruiting

This clinical trial investigates the best way to use prone position placing patients on their stomachs for adults with moderate to severe Acute Respiratory Distress Syndrome ARDS who need mechanical ventilation. Researchers want to find out if longer prone sessions lasting more than 48 hours improve survival compared to daily sessions lasting 16 to 24 hours. The study also evaluates the safety of prolonged prone positioning and its impact on medical problems related to this intervention. Participants are randomly assigned to one of two groups one receiving prolonged prone position sessions lasting at least 48 hours and up to 120 hours until their oxygenation improves, and the other receiving intermittent daily prone sessions lasting between 16 and 24 hours. Both groups may have repeated prone sessions during the first 7 days if their oxygen levels fall below a certain threshold after returning to the supine position. This design allows comparison of continuous versus intermittent prone positioning in managing ARDS. During the study, participants will be followed for up to 90 days to monitor their clinical progress. Researchers will assess outcomes including mortality at 28 and 90 days, ventilator-free days, and hospital-free days at 28 days. Safety and adverse events related to prone positioning will also be recorded. The total participation involves receiving the assigned prone sessions during the first week and ongoing clinical follow-up to evaluate the effectiveness and safety of each approach.

Age: 18Years +All GendersPhase Not Applicable
38 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the DIAGEN-IA diagnostic support platform, designed to help identify pediatric neurological diseases with a genetic basis. The study aims to see if the platform reduces inappropriate referrals to clinical geneticists, improves the completeness of initial diagnostic evaluations, enhances referral quality, and increases user satisfaction. Conducted at Carlos Van Buren Hospital in Chile, the trial uses a prospective before-and-after design to compare outcomes between baseline and intervention phases. The study includes two 6-month phases. In the first phase, baseline data on referral appropriateness and evaluation completeness are collected without the platform. In the second phase, pediatric neurologists trained to use DIAGEN-IA will use the platform during consultations to guide referrals and recommend diagnostic tests. The platform uses a Bayesian network model integrating medical ontologies to suggest diagnoses and tests based on clinical data. Usage of the platform, including login frequency and evaluations performed, will be monitored. Participants include healthcare professionals providing care to children under 18 years old and responsible for referring suspected rare disease cases to clinical geneticists. The study collects demographic data and monitors referral appropriateness using a 5-point Likert scale, referral quality based on standard criteria, and user satisfaction via questionnaires at one and six months. Data will be anonymized, and the results aim to improve referral processes and diagnosis in pediatric neurological care.

All AgesAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Healthy Volunteer

This research aims to assess the feasibility and early effectiveness of a mental health literacy MHL program designed for teachers and parents to support the mental health of children aged 8 to 11 years in primary schools located in vulnerable communities in Chile and Ecuador. It addresses the high prevalence of child mental health problems and the gap in treatment access in Latin America by improving knowledge and confidence in recognizing and managing mental health issues within schools and families. The study builds on a previous project that showed benefits from teacher-focused MHL training and expands it by including parents and evaluating child outcomes across two countries. The intervention includes a teacher program consisting of six 2-hour participatory workshops covering topics like self-care, child development, anxiety, depression, suicide prevention, behavioral disorders, autism, and child maltreatment. Parents participate in three 90-minute educational sessions focusing on stigma, social support, healthy development, and emotional containment. The study involves seven primary schools randomly assigned to either the intervention or control group, with approximately 230 children, their parents, and teachers participating. Data collection occurs before and after the intervention using validated tools. Participants will be involved in assessments including surveys and biological measures such as cortisol levels in fingernails to evaluate stress. Researchers will measure changes in mental health literacy among parents and teachers, emotional wellbeing of adults, child mental health problems, and intervention feasibility indicators like retention and satisfaction. The study combines quantitative and qualitative methods, including focus groups, to understand the programs acceptability and cultural fit, with follow-up lasting up to 16 weeks post-intervention.

Age: 5Years +All GendersPhase Not Applicable
3 locations
E

Actively Recruiting

Researchers are evaluating zilovertamab vedotin for its safety and effectiveness in children and young adults aged 6 to 25 years who have certain blood cancers such as B-cell acute lymphoblastic leukemia B-ALL, diffuse large B-cell lymphoma DLBCLBurkitt lymphoma, or solid tumors including neuroblastoma and Ewing sarcoma. This phase 12 study aims to better understand how well this treatment works and its safety profile in these pediatric and young adult patients with relapsed or refractory disease. Participants receive escalating doses of zilovertamab vedotin through intravenous infusion on the first day of each 21-day treatment cycle. The study involves a single group where all participants are given the study drug, and dosing adjustments are made based on tolerability and response. Treatment may continue across multiple cycles up to approximately 54 months, with assessments for dose-limiting toxicities, adverse events, and treatment responses. Throughout the study, participants undergo regular monitoring including blood tests to measure drug levels, safety labs, and evaluations of disease response. Outcome measures include the number of participants experiencing adverse events, dose modifications, and objective response to treatment. Long-term safety and effectiveness are tracked over the course of the study, which may last up to several years, ensuring careful observation of treatment impact and participant well-being.

Age: 6Months - 25YearsAll GendersPhase 1Phase 2
71 locations